Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis
Authors:
Open Access
- 24 November 2016
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 128 (21) , 2533-2537
Abstract
Key Points: A BRAF gene fusion and small in-frame BRAF deletions were found in a subset of LCH lesions lacking BRAF-V600E or MAP2K1 mutations. In LCH model systems, responses to MAPK pathway inhibitors depend on the specific genetic alteration that drives ERK activation.Keywords
This publication has 27 references indexed in Scilit:
- Somatic activating ARAF mutations in Langerhans cell histiocytosisBlood, 2014
- Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndromeJournal of Experimental Medicine, 2013
- Pathological Consequence of Misguided Dendritic Cell Differentiation in Histiocytic Diseases2013
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- The Structural Basis for Control of Eukaryotic Protein KinasesAnnual Review of Biochemistry, 2012
- Genomic Complexity and AKT Dependence in Serous Ovarian CancerCancer Discovery, 2012
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaNature Medicine, 2010
- Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic AstrocytomasCancer Research, 2008
- Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for TherapyPLOS ONE, 2007